The real impact of RVU cuts in electrophysiology | TAVR changes on the way | Cardiology groups celebrate bill | BP drug recalled

Despite a substantial increase in demand for electrophysiologists, payments for their services have remained stagnant. 

After months of consideration, CMS has proposed sweeping changes to its TAVR coverage policies. The agency is accepting public comments until July 15.

Major TAVR policy changes appear to be on the way—should clinicians be excited or concerned? Leading U.S. medical societies are sharing their early reactions.

Physicians from all specialties, not just cardiology, have been hoping for legislation like this for years.

Certain lots of a popular diuretic have been recalled due to concerns about the drug's effectiveness. 

These programs may provide benefits in some cases. In others, however, there is a concern that they could actually lead to higher costs over time.

Samuel Jones, MD, reviews some of the biggest concerns about a new Medicare payment model focused on heart failure care that goes live in 2027. 

The Thunderbolt device from California-based Penumbra uses modulated aspiration to detect and remove blood clots. Back in January, Boston Scientific agreed to acquire Penumbra for approximately $14.5 billion.

The new recall impacts thousands of portable systems. A software update is now available that should resolve any issues.